Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Pasterczyk, Katarzyna" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
Prevention of seizures after ischemic stroke: association between statin use and the risk of seizures
Autorzy:
Marciniec, Michał
Popek-Marciniec, Sylwia
Kulczyński, Marcin
Pasterczyk, Katarzyna
Szczepańska-Szerej, Anna
Rejdak, Konrad
Powiązania:
https://bibliotekanauki.pl/articles/1177817.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
HMG-CoA reductase inhibitor
Post-stroke seizure
epilepsy
ischemic stroke
rt-PA
statin
Opis:
More than 50 million people worldwide suffer from epilepsy. In approximately 50% cases of newly diagnosed patients over 60 years of age seizures are related to stroke. Post-stroke lesions in brain tissue may result in 7 fold increase risk of seizures compared to the general population. The most significant risk factors for post-stroke seizures (PSS) and post-stroke epilepsy (PSE) include stroke severity, intracerebral or subarachnoid hemorrhage and cortical involvement. Increased incidence of PSS was also observed in younger patients especially with previous early PSS occurrence. Statins (HMG-CoA reductase inhibitors) are a class of lipid-lowering medications characterized by neuroprotective and antiepileptic effects. The main result of the performed studies was significantly reduced risk of developing PSS associated with a post-stroke, but not pre-stroke statin use. Moderate to high doses of statin and early administration in acute phase of stroke potentiated the beneficial effects of the treatment. The evidences for the association between PSS prevention and statin treatment become more significant, however the most recent AHA/ASA recommendations do not include any medications in the PSS prophylaxis. This article summarizes the current knowledge about the prediction and prevention of PSS and PSE.
Źródło:
World Scientific News; 2018, 99; 181-192
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The effectiveness of patent foramen ovale closure and antiplatelet or anticoagulant therapies for cryptogenic ischemic stroke
Autorzy:
Marciniec, Michał
Szczepańska-Szerej, Anna
Kulczyński, Marcin
Popek-Marciniec, Sylwia
Pasterczyk, Katarzyna
Rejdak, Konrad
Powiązania:
https://bibliotekanauki.pl/articles/1177466.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
Anticoagulation Agents
Antiplatelet Agents
Cerebral Infarction
Cerebrovascular Stroke
Patent Foramen Ovale
Opis:
Patent foramen ovale (PFO) occurs in approximately 50% cryptogenic strokes cases. One of the most clinically important consequences of PFO is paradoxical embolization of venous thrombus resulting in recurrent stroke. The aim of this meta-analysis is to compare the efficacy and safety of PFO closure and antiplatelet or anticoagulant therapy alone (medical therapy, MT) in the secondary stroke prevention. Eligible studies for meta-analysis published from May 2008 to May 2018 were identified through a search of PubMed database and two clinical trial registries websites: ClinicalTrials.gov and EU Clinical Trials Register. A meta-analysis was conducted with the use of Statistica software version 13.1. Three studies comprising 2’307 patients were included. The main outcomes were: recurrent stroke occurrence during follow-up period, the frequency of serious adverse events (SAE) and the mortality rate. Statistical significance was found in the assessment of recurrent stroke occurrence when the comparison referred to PFO closure and antiplatelet therapy (RR 0,30, p < 0,05, 95% CI 0,11 – 0,85). There were no significant differences between PFO closure and MT in the frequency of SAE occurrence (RR 1,03, p = 0,73) and mortality rates (RR 0,69, p = 0,39). Current clinical data indicate that PFO closure devices applied to the carefully selected group of young and middle-aged patients with cryptogenic ischemic stroke may be as or more effective than antiplatelet therapy.
Źródło:
World Scientific News; 2018, 102; 47-58
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies